- Conditions
- Nontuberculous Mycobacterial Pulmonary Infection, Outbreak Investigation, Healthcare Associated Infection, Mycobacterium Infections
- Interventions
- Epidemiologic investigation
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 1 Month to 99 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Major Cutaneous Abscess, Cellulitis, Erysipelas
- Interventions
- TR701 FA
- Drug
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 10
- States / cities
- Anaheim, California • Buena Park, California • Chula Vista, California + 7 more
- Conditions
- Staphylococcus Aureus
- Interventions
- Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo
- Biological
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Fort Sam Houston, Texas • Portsmouth, Virginia
- Conditions
- Clostridium Difficile Infection
- Interventions
- Vancomycin Oral Capsule, Placebo Oral Capsule
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Contraception, Tuberculosis
- Interventions
- Rifampin 600 MG
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Staphylococcal Skin Infections, Wounds and Injuries, Abscess, Cellulitis, Streptococcal Infections
- Interventions
- oritavancin
- Drug
- Lead sponsor
- Targanta Therapeutics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 33
- States / cities
- Mobile, Alabama • Anaheim, California • Buena Park, California + 29 more
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Interventions
- Boostrix™, ADACEL®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 19 Years to 64 Years
- Enrollment
- 2,337 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 36 more
- Conditions
- Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
- Interventions
- Vancomycin, Placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
- Interventions
- CF-301, Placebo
- Biological · Drug
- Lead sponsor
- ContraFect
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more
- Conditions
- Staphylococcal Infections, Chronic Kidney Failure
- Interventions
- Staph aureus types 5 and 8 conjugate vaccine, placebo
- Biological
- Lead sponsor
- Nabi Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Botulism, Iatrogenic Botulism
- Interventions
- Amifampridine
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Clostridioides Difficile Infection Recurrence
- Interventions
- Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.
- Other
- Lead sponsor
- Bactolife A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Royal Oak, Michigan • Rochester, Minnesota + 1 more
- Conditions
- Healthy
- Interventions
- Anthrax Vaccine Adsorbed, Saline injection
- Biological
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years to 61 Years
- Enrollment
- 1,564 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2010
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Silver Spring, Maryland + 2 more
- Conditions
- Pneumococcal Disease
- Interventions
- 31-valent pneumococcal conjugate vaccine, PCV20
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 30
- States / cities
- Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
- Conditions
- Group B Streptococcal Infections
- Interventions
- IVT GBS-06, Placebo
- Biological
- Lead sponsor
- Inventprise Inc.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Meningococcal Meningitis
- Interventions
- Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
- Biological
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 801 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Fremont, California • Madera, California + 14 more
- Conditions
- Pneumococcal Infection
- Interventions
- V116, PCV20
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,663 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 52 more
- Conditions
- Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
- Interventions
- TBAJ-876, Midazolam, Digoxin
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Staphylococcus Aureus, HIV Infections
- Interventions
- rifabutin plus trimethoprim sulfamethoxazole, placebo plus trimethoprim-sulfamethoxazole
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae, Asymptomatic Infections
- Interventions
- Resistant Potato Starch, Maltodextrin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Wound Infection Due to Staphylococcus Aureus, MRSA Infection of Postoperative Wound
- Interventions
- antiseptic bundle, standard of care
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Tuberculosis
- Interventions
- Moxifloxacin, PA-824, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Streptococcal Infections
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Pneumococcal Disease
- Interventions
- PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 4,701 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Lake Forest, California • Walnut Creek, California + 29 more